Background: Systemic glucocorticoids are often used in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), and osteoporosis is a well-known complication to steroid treatment, associated with significant morbidity. Nevertheless, the burden of steroid induced osteoporosis is unknown in patients with CRSwNP. We aimed to assess the risk of acquiring osteoporosis caused by oral steroids in patients with CRSwNP, and provide recommendations on future research and guidelines.
Introduction
Treatment with oral glucocorticoids is common for patients with nasal polyps (NP, also named chronic rhinosinusitis with polyps, CRSwNP) with or without asthma (1) . A commonly suggested regimen for adults is 0.5-1.0 mg/kg of prednisolone or prednisolone equivalent daily for 5-14 days, in combination with a topical nasal steroid (1, 2) . According to EPOS2012, a short course of oral steroids improves symptoms and causes reductions in polyp size and should be considered for severe NP (3) . However, oral steroids cause several adverse effects; here amongst disruption of the hypothalamic-pituitary-adrenal axis, hyperglycemia and glucose intolerance, gastrointestinal ulcer and osteoporosis (3, 4) . The percentage of CRSwNP patients treated with systemic steroids and the burden of osteoporosis in these patients is unknown. However, this adverse effect of systemic steroids is well known from studies of other patient categories. One of these studies suggests that the current population at risk of developing glucocorticoid-induced fractures in the UK may be as large as 350,000 individuals, and that the vast majority of these individuals have not been evaluated for the risk of osteoporosis, or received preventive treatment (5) . In accordance with this, we expected to find an increased prevalence of osteoporosis in patients with CRSwNP treated with systemic steroids.
Osteoporosis is a systemic skeletal disease characterized by low the prevalence of LBD or osteopenia/osteoporosis was overall 38.6%. The older patient groups had a greater prevalence of osteopenia/osteoporosis or LBD (p < 0.0001), and the study showed insignificant differences between men and women.
The study concluded that cumulative steroid doses correlated strongly with loss of bone density, regardless of age, gender, and underlying disease. Consequently, this effect could be more problematic in younger patients who will be at higher risk of bone loss with accruing doses of oral steroids. However, this recommendation is not substantiated in the study, since the study does not cover accumulated doses during lifetime.
A prospective, uncontrolled trial (n=46) studied osteoporosis after oral steroid treatment in patients with CRSwNP (associated with asthma and/or aspirin intolerance) (9) . This study is an extension of a trial by Nores et al. (10) with partly the same patient population. Patients had taken at least four courses of oral steroid during the past 12 months. Each course consisted of prednisolone 1 mg/kg body weight/day for 6 to 10 days. This would indicate a cumulative dose as high as 600 mg of oral steroid for a 60 kg patient per ten-day course.
The mean duration of treatment was 4.7 years (SD=4.2, range 1-22). The mean number of oral steroid courses per year was 6.8 (SD=4.7, range 4-26). The study only mentions the number of postmenopausal women (n=7) but no further details are given on demographics. There is no information about preventive treatment despite the high steroid dosage. A DXA scan was carried out at least once for each patient and the T-score was calculated for three different sites; lumbar spine, femoral neck and proximal femur. The study showed a high prevalence of osteoporosis and osteopenia (12.2% and 48.8%, respectively) at the lumbar spine, compared to the normal population as referenced in the study.
In conclusion, the patients with severe NP and a high steroid consumption had a high prevalence of steroid induced osteoporosis.
Risk of bias in the included studies
Rajasekaran et al. studied patients recruited from tertiary care; bone density resulting in decreased bone strength, increased bone fragility and consequently risk of fracture (6) . 
Materials and methods
In Fibrosis. The following data were extracted: demographics, oral steroid dose, BMD (T-and Z-scores), nasal symptoms and preventive treatment. All studies were assessed for the risk of bias using "The Cochrane Collaboration's tool for assessing risk of bias" (7) .
Finally, we retrieved guidelines for the management of NP and treatment with oral steroids.
Results
We identified 14 eligible trials from which two (n=243) met the inclusion criteria. The trials were conducted between 1990 and 2015 ( Figure 1 , Tables 1, 2) .
A retrospective, uncontrolled trial (n=197) evaluated the degree of osteoporosis in patients with chronic rhinosinusitis (CRS) with nasal polyps (n=176) and without nasal polyps (n=21); 81.7%
had concomitant asthma (8) . Participants had been DXA scanned less than five years prior to inclusion and had taken oral steroids (>5 mg daily) for at least three months before inclusion, which is much longer than the commonly suggested treatment postmenopausal women had a statistically higher prevalence of osteoporosis or LBD when compared with younger men and premenopausal women (8) . This result was adjusted for age and 
. This is a remarkable high prevalence of osteoporosis compared to the prevalence of osteoporosis in the US population: 10% of Americans over age 50 are estimated to have osteoporosis (11) . The given doses correspond to 480 mg per course for a 60 kg patient during an therefore, patients with a more severe disease were selected over other patients (8) . In addition, recall bias and selection bias must be considered due to inclusion of patients with a previous DXA scan. Finally, the study was uncontrolled.
The study by Bonfils et al. was also uncontrolled and fails to describe from where and how patients were recruited (9) . This unusually high number of oral steroid courses may indicate that the patients treated in this study were selected. Furthermore, there is no information of previous DXA scans and it is unclear whether the patients had low BMD before the therapy started, (Table 3) .
Discussion
The aim of this study was to review the literature on the risk of osteoporosis in CRSwNP patients taking oral glucocorticoids.
The two studied trials, both with considerable bias, concluded that oral steroids increase osteoporosis in patients with CRSwNP.
The limited available data and the high risk of bias entails that the studies are too heterogeneous to enable a meta-analysis. Due to the limited number of trials found, we compared guidelines for prevention of corticosteroid-induced osteoporosis in other diseases (Table 4) .
A commonly suggested regimen for adults with CRSwNP is 0.5 mg/kg daily for 5-10 days (1, 2) . There is only scant information on the effect on BMD and the risk of fractures associated with courses of that duration. However, in a study of patients who received high doses of oral steroids (20 to 40 mg daily)
for a similar duration (3-14 days), a significantly greater loss in Table 4 . A summary of the studied guidelines. Guidelines for preventive treatment of glucocorticoid induced osteoporosis, not specifically related to
CRSwNP.
* Measured as T-score.
Study
Random sequence generation (1) Allocation concealment (1) Blinding of participants and personnel (2) Blinding of outcome assessment (3) Incomplete outcome data objective outcomes (4) Incomplete outcome data subjective outcomes (4) Selective reporting (5) Other bias Comment
Summary risk of bias
Rajasekara et al. 2010 (8) High High High High Low Low Low High Not randomized and no control group. Patients were recruited from tertiary care, which may create selection bias; patients with a more severe disease were selected over other patients. The retrospective study is subject to recall bias and selections bias due to the collection of those who had undergone BMD testing.
High Bonfils et al. 2006 (9) High High High High High Low Low High Not randomized and no control group. Not described where and how the patients were recruited. Unusually high number of oral steroid courses may indicate that the patients treated in this study were selected. No information of previous DXA scans and it is unclear whether the patients had low BMD before the therapy started.
High Table 3 . Risk of bias in the two included CRSwNP studies. We did not find any reports indicating that the adverse effects of oral steroids should be different in CRSwNP patients than in patients treated for other diseases. Thus we reviewed general guidelines for glucocorticoid-induced osteoporosis, not specifically related to CRSwNP and we believe that these guidelines may also support future recommendations for CRSwNP (Table   4 ). The recommended preventive treatment varies greatly between the guidelines, and there is sparse information on how to maintain satisfying results. Although the greatest increase in risk is observed with higher dose therapy, increased risk is reported with doses as low as 2.5 mg daily of oral steroids after three months of treatment while other studies report an increased risk at 7.5 mg daily (5) . Clearly, the risk of bone fracture is increased by oral steroids as a result of induced osteoporosis. In addition to this effect, however, oral steroid may also cause low energy fractures by a mechanism unrelated to bone decalcification. It has been suggested, although not confirmed in recent studies that glucocorticoid-induced fractures occur at a higher BMD than in age-related or postmenopausal osteoporosis. Therefore, the studied guidelines recommend preventive treatment at a higher T-score (<-1 or <-1.5) (5, 6, 16, 17) . A yearly DXA scan and life style counselling including regular muscle-strengthening exercises are recommended (5, 6) . A follow-up of patients receiving any dose of oral steroids and a fall risk assessment is recommended as well as an evaluation for prevalent fragility fractures and a vertebral fracture assessment or radiographic imaging of the spine (16) . A DXA scan is suggested at doses of 37.5 mg oral steroids for 10 days and should be carried out before the treatment and a follow up is recommended after two years regardless of dose and duration (14) . Patients with fragility fracture or with one or more risk factors for osteoporosis treated with oral steroids equivalent to prednisolone >5 mg daily for more than 3 months should also be DXA scanned (17) (Table 5) .
Common for these guidelines is that they recommend DXA (3) . A DXA scan every two years is worth considering.
BMD was seen in patients receiving > 2.5 courses per year (n = 9) compared with those receiving sporadic courses, i.e. ≤ 2.5 courses per year (n = 26) (12) . From this we conclude that infrequent usage (< 2. (≥ 30 mg) was associated with only a small increased risk of osteoporotic fracture (13) .
In a meta-analysis, Van Staa et. al. conclude that the daily rather than the cumulative, dose of glucocorticoids was found to be a strong predictor of vertebral fracture in patients receiving oral steroids (14) . This is in contrast to recommendations in the studied guidelines where the cumulative dose is considered to be the most important factor for preventive therapy. At similar levels of BMD, postmenopausal women taking oral steroids, as compared with controls, had considerably higher risks of fracture. There was not enough data to establish whether the intervention threshold should be a T-score of -1.0 or -1.5. The study also supported the hypothesis that treatment with oral steroids influences the occurrence of fracture by a mechanism independent of BMD. Vestergaard et al. found that oral prednisolone/ prednisone was associated with a dose-dependent increase in fracture risk starting from a dose of 7.6-10 mg/day even with a duration of <60 days (15) . Table 5 . Risk factors that contribute to osteoporosis and fractures.
Risk factor
High intake of oral glucocorticoids (6, 12, 16) ≥5 mg/day of prednisone for ≥3 months (6) or high cumulative glucocorticoid dose (16) or >2.5 short courses per year, (20-40 mg glucocorticoid for 3-14 days) (12) Age (6) Women >65 years Men > 70 years
Prior osteoporotic fracture (6) Low body mass index (6, 16) Parental history of hip fracture (6, 16) Smoking (6, 15) Excessive alcohol consumption (6, 16) ≥3 drinks/day
Femoral neck BMD (6) Vitamin D insufficiency (6) It has been shown that doses of steroids commonly used for patients with CRSwNP can lead to an increased risk of osteoporosis as well as for osteopenia and fractures, while greater doses increase the risk substantially. However, it remains to be shown that this is valid for patients with CRSwNP. Until further trials have been presented we recommend that the general guidelines (5, 6, 16, 17) for glucocorticoid induced osteoporosis, not specifically related to CRSwNP should be used ( Table 4 ), and that the recommended preventive treatments should be followed.
There is limited information available about the risks associated with courses as short as 3-14 days and therefore we recommend that great attention should be paid to the risk of osteoporosis even in treatment with such short courses. There seems to be no consensus on the doses and durations of steroids before preventive treatment should be initiated, and from the studies presented here, we know that they vary widely.
Furthermore, it is unknown whether co-existing asthma affects the risk of osteoporosis. Studies have found adverse effects from doses as low as 2.5 mg daily (5) and there is no consensus about whether the daily or cumulative dose is the most important risk factor (13) . Future randomized controlled trials would be needed 
Conclusion
Oral steroids with variable doses and durations administered in patients with nasal polyps with or without asthma were found to increase osteoporosis in the two included trials; however, we were unable to assess the risk of osteoporosis caused by oral steroids from these trials. We found no information on the effect of the preventive treatment.
